“Long-acting medications to treat schizophrenia can improve the lives of patients,” said Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “Having a variety of treatment options and dosage forms available for patients with mental illness is important so that a treatment plan can be tailored to meet the patient’s needs.”

Aristada injectable suspension will be available in 441mg/1.6mL, 662mg/2.4mL, and 882mg/3.2mL strengths. The kit contains a 5mL prefilled syringe and safety needles. Aristada is set to launch immediately. Aristada must be dispensed with a patient Medication Guide that describes important information about the drug’s uses and risks.

For more information call (866) 274-7823 or visit Aristada.com.